Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 82M | 23.8% |
| Gross Profit | 74M | 29.8% |
| Cost of Revenue | 7.5M | 15.2% |
| Operating expense | 96M | 17.9% |
| Net Income | -16M | 36.6% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 352M | 2.4% |
| Total Liabilities | 213M | 6% |
| Total Equity | 139M | 2.6% |
| Shares Outstanding | 120M | 5% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | 320,000 | 101.1% |
| Cash from financing | 1.4M | 249.4% |
EPS
Financial Highlights for Arcutis Biotherapeutics in Q2 '25
Arcutis Biotherapeutics reported a revenue of 82M, which is a 23.8% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 74M, marking a 29.8% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 7.5M, a -15.2% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 96M, showing a 17.9% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -16M, showing a 36.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
It was a positive quarter for Arcutis Biotherapeutics with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
